Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib or Dasatinib with Chemotherapy in Ph-Like ALL
NCT02420717Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2015
- Primary completion
- Jan 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib, dasatinib in Acute lymphoblastic leukemia (Philadelphia-chromosome-like), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2015; status: terminated.
02
Drugs
ruxolitinibdasatinib
03
Conditions
Acute lymphoblastic leukemia (Philadelphia-chromosome-like)
Beyond the preview
Go deeper on NCT02420717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02420717.